



PATENT

Attorney Docket No. 39780-2630P1C21 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ashkenazi et al. Docket No.: 39780-2630P1C21  
Serial No.: 09/978,423 Group Art Unit: 1648  
Filing Date: October 16, 2001 Examiner: Le, Emily M.  
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME**

Express Mail No.: EL 976 543 704 US  
Mailing Date: October 14, 2004

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

MS: FEE AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

10/21/2004 AWONDAF1 00000018 081641 09978423  
02 FC:1806 180.00 DA

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2630P1C21).


Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: October 14, 2004

By: Leslie A. Mooi  
Leslie A. Mooi, Reg. No. 37,047

275 Middlefield Road  
Menlo Park, CA 94025-3506  
(650) 324-7000  
Customer No. 35489

<b>INFORMATION DISCLOSURE STATEMENT</b>  PTO-1449		ATTY. DOCKET NO.		SERIAL NO.			
		39780-2630P1C21		09/978,423			
		APPLICANT <i>Ashkenazi et al.</i>					
		FILING DATE 10/16/2001		GROUP: 1648			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	FILING DATE		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO99/46281 A2	09-1999	World			<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Bollinger, Marc F. <i>et al.</i> , "Identification of a Novel Neuroligin in Humans which Binds to PSD-95 and Has a Widespread Expression," <i>Biochem J.</i> , 356: 561-588 (2001)						
	Dayoff, P_KIAA0951, Submitted 04 February 1999.						
	Jamain, Stephane <i>et al.</i> , "Mutations of the X-Linked Genes Encoding Neuroligins NLGN3 and NLGN4 are Associated with Autism," <i>Nature Genetics</i> , 34: 27-29 (2003)						
	Kandel, Eric R. <i>et al.</i> , Eds., "Part VIII / The Development of the Nervous System," <i>Principals of Neural Science Fourth Edition</i> , 1056 (2000)						
	Nagase et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New cDNA Clones from Brain which Code for Large Proteins <i>in vitro</i> ," <i>DNA Res.</i> 6:337-345 (1999)						
	Sequence Alingment of SEQ ID NO: 375 with NLG4_Human of Nagases et al. ( <i>DNA Res.</i> 6. 337-345)(1999) Database SwssProt_41						
	Grisaru et la., Structural roles of acetylcholinesterase variants in biology and pathology. <i>Eur. J. Biochem.</i> 241, 1999, pages 672-686						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.